The Buffett Lens

Folks, digging into a business like Halozyme Therapeutics feels a bit like sizing up the neighbor who invented a special attachment for the garden hose that lets everyone water their plants deeper and faster without wasting a drop. He doesn't grow the tomatoes himself, but the big outfits with the fancy greenhouses pay him a tidy sum every time they hook up his gadget. That's the essence here – they've got this enzyme technology that helps big drug makers deliver their heavy medicines through simpler injections, and it seems to be catching on.

What catches my eye first is how they've been putting the owners' capital to work. Revenue has climbed steadily from next to nothing to around four hundred million in recent quarters, with net income following along to about three hundred million over the last four quarters. That translates into returns on equity north of 150 percent lately, and averaging close to that over five years. As I've noted before, the true test of a business isn't just whether earnings per share tick up each year, but whether it delivers a high rate of return on the equity capital employed without leaning on accounting tricks. This outfit clears that bar by a wide margin, and it looks like the managers running the day-to-day have built most of that extra value themselves by finding the right partners and keeping the technology humming.

Their edge comes from patents and know-how around this recombinant enzyme, which acts like a protective wall around a valuable piece of pasture. Competitors can't just wander in and copy the formula overnight. In that sense, it's a business boat with decent fundamental economics, not one where even the smartest rowers would struggle against a leaky hull. The high institutional ownership suggests plenty of folks see the same thing, though the low insider stake keeps me from getting too carried away with any single person's genius.

Still, I always try to look at the other side of the ledger with some humility. They've taken on debt nearly ten times their equity, and that leverage can juice the returns when things go well but turn sour if the healthcare winds shift. I've seen how inflation or a sudden change in customer needs can make borrowed money feel a lot heavier than it did on the way up. This field also carries the usual uncertainties of drug development – regulations can tighten, partners might develop their own workarounds, or a better idea could come along from somewhere else. On top of that, the market is valuing the book at over thirty times, which means we're mostly paying for the expected future growth rather than the assets sitting there today. That premium demands a clear margin of safety, because past rates of expansion rarely repeat themselves forever.

Over the long haul, if they keep protecting that technology, manage the borrowing carefully, and let earnings compound without chasing every new fad, this could turn into a sensible holding for the patient owner. The key is focusing on the real worth of the enterprise rather than short-term price swings, and only stepping in when the price makes sense relative to what the business can deliver year after year.

For those looking to act on this, the ticker for Halozyme Therapeutics, Inc. on eToro is $HALO.

Match Group strikes me as a bit like the proprietor of a sprawling county fairground where people come not just to stroll but to find someone special to share the evening with. The owner doesn't need to do the matchmaking himself; he simply keeps the grounds inviting, charges a modest fee for entry or extras, and watches as the crowds grow because more folks mean better odds of a good connection, which in turn draws even more visitors the next time around.

This outfit has a moat of sorts, much like a castle protected from invaders by its network effects and collection of well-known brands such as Tinder and Hinge. The more users join, the richer the pool becomes for everyone, creating a self-reinforcing loop that competitors find hard to break into overnight. I have long favored businesses where the underlying economics do the heavy lifting rather than relying on a single brilliant manager rowing against a poor current, and here the data shows revenue climbing steadily across recent quarters to a last-twelve-months figure of $3.5 billion, with net income reaching $0.7 billion. That kind of consistent earning power, paired with virtually no debt on the balance sheet, lines up with my preference for operations that avoid leverage or accounting tricks. The valuation at roughly thirteen times earnings and an enterprise multiple around eleven times EBITDA strikes me as sensible, not inflated, especially when weighed against the reported Buffett score of about sixty-eight out of a hundred. In my letters over the years I have stressed that what counts is the rate of return on equity capital employed without undue leverage, and while the numbers here are not perfect, the absence of heavy borrowing gives the business room to compound if the user base holds steady.

Still, I must acknowledge the shortcomings with the same candor I apply to my own holdings. The latest and five-year average return on equity both register at zero percent, which falls far short of the high earnings rates on capital that have always been my primary test for managerial performance. That figure makes me pause, as it hints that the business may not be generating the kind of owner-friendly returns I seek even after accounting for growth. Insider ownership sits at just 0.7 percent, a low level that leaves me wondering whether the managers have enough skin in the game to weather the inevitable bumps. The dating industry itself can shift with user habits, new apps, or even regulatory winds, and what looks like a durable network today could face pressure if people tire of the digital format or migrate elsewhere. I have seen plenty of fine businesses lose their edge when the boat itself turns leaky, no matter how skilled the crew.

Over the long term, Match Group could still offer sensible value for patient owners who are willing to look beyond short-term fluctuations and focus on whether the moat deepens and intrinsic value grows. Past rates of growth cannot be counted on to repeat, as I have noted before, yet at a market capitalization of $8.4 billion and a share price near $36, the setup does not demand heroic assumptions to imagine decent returns if earnings hold and capital is deployed wisely. I have always counseled that time is the friend of the wonderful business, and this one might reward those who buy with a multi-year horizon rather than expecting quick fireworks. For those looking to act on this, the ticker for MTCH on eToro is $MTCH.